These studies, together with our evaluation of thalidomide in a mouse transgenic model of Alzheimer’s disease in which it lacked efficacy and failed to lower elevated brain levels of TNF-α at a clinically translatable dose [65], focused our attention to more potent anti-inflammatory analogs [21], including Pom. Here, TNF is linked to Alzheimer disease.